GlassScriptPhysician profile
Steven W Johnson
NPI 1700853058
$2,168.41
in general payments reported to CMS, 2019-2025
25 companies · $95.79 in 2025
The $95.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $565 · 2021: $679 · 2022: $335 · 2023: $115 · 2024: $161 · 2025: $95.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $488.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $385.25 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $168.13 | 2019-2024 | Veozah |
| Novo Nordisk INC | $167.38 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $114.07 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $100.79 | 2023-2025 | |
| Amgen INC. | $94.88 | 2020-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.60 | 2019-2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $64.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $62.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.60 | 2022 | |
| Merck Sharp & Dohme LLC | $41.34 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $36.51 | 2022 | |
| Esperion Therapeutics, INC. | $34.67 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $29.17 | 2023 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $28.62 | 2025 | Daybue |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.23 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $24.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.36 | 2022 | |
| Radius Health, INC. | $18.24 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.30 | 2020 | |
| Abbvie INC. | $14.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.